4,220 IQVIA Holdings Inc. $IQV Shares Sold by Eagle Rock Investment Company LLC

Eagle Rock Investment Company LLC trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 6.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 57,338 shares of the medical research company’s stock after selling 4,220 shares during the period. IQVIA makes up about 1.8% of Eagle Rock Investment Company LLC’s holdings, making the stock its 15th biggest holding. Eagle Rock Investment Company LLC’s holdings in IQVIA were worth $15,415,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. BlackRock Inc. acquired a new stake in IQVIA in the 2nd quarter valued at $2,811,292,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of IQVIA by 9.0% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company’s stock worth $315,772,000 after purchasing an additional 134,997 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in IQVIA by 4.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company’s stock worth $282,657,000 after buying an additional 66,643 shares during the period. Canada Pension Plan Investment Board purchased a new stake in shares of IQVIA during the second quarter worth about $240,911,000. Finally, Bank of America Corp DE purchased a new position in IQVIA in the second quarter valued at about $235,551,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently issued reports on IQV shares. TD Cowen upped their price target on shares of IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. UBS Group assumed coverage on IQVIA in a report on Wednesday, September 30th. They issued a “buy” rating and a $345.00 price target for the company. Truist Financial restated a “buy” rating and issued a $329.00 target price (up from $300.00) on shares of IQVIA in a research note on Monday, September 28th. Mizuho raised their target price on IQVIA from $275.00 to $300.00 and gave the company an “outperform” rating in a research note on Wednesday, October 7th. Finally, BMO Capital Markets boosted their price objective on IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $276.00.

IQVIA Stock Up 3.3%

NYSE IQV opened at $276.56 on Thursday. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $277.40. The company has a market capitalization of $45.52 billion, a P/E ratio of 23.58, a PEG ratio of 2.35 and a beta of 1.17. The company’s 50 day simple moving average is $262.40 and its 200 day simple moving average is $215.24. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. The business had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same period last year, the company posted $2.81 EPS. The company’s revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities research analysts expect that IQVIA Holdings Inc. will post 11.55 earnings per share for the current fiscal year.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider directly owned 2,989 shares in the company, valued at $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider W. Richard Staub sold 5,500 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the sale, the insider owned 13,312 shares of the company’s stock, valued at $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 15,581 shares of company stock valued at $3,796,021 in the last quarter. Corporate insiders own 1.70% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.